PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

August 5, 2024

On July 30, 2024, PepGen announced positive data from the low-dose (5 mg/kg) cohort of PGN-EDO51 in the ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for the treatment of Duchenne Muscular Dystrophy.

To read more, please click here.

Jett Foundation’s Silver Soirée
Thursday, June 11, 2026 | 5:30PM
Granite Links | Quincy, MA